Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10546MR)

This product GTTS-WQ10546MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ10546MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10878MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ15271MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ825MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ6046MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ3543MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAX069
GTTS-WQ8158MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ3402MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aALB03
GTTS-WQ10138MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LAG-525
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW